Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HCK | P08631 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | ITK | Q08881 | 5/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719272 | 0.84 | ITK (0.43) | KMT2ANR1H2NR1H3EGFRITK | |
| SCHEMBL10117911 | 0.78 | PIK3CD (0.43) | NR1H2NR1H3PIK3CDABL1EGFR | |
| SCHEMBL3835028 | 0.77 | MAPT (0.43) | KMT2AMEN1NR1H2PIK3CDABL1 | |
| SCHEMBL2458509 | 0.77 | ACLY (0.52) | NR1H2NR1H3PIK3CDABL1EGFR | |
| SCHEMBL15969036 | 0.77 | PPARG (0.43) | NR1H2NR1H3PIK3CDABL1EGFR | |
| SCHEMBL6394140 | 0.76 | PIK3CD (0.45) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL17782354 | 0.76 | NR1H2 (0.42) | NR1H2NR1H3PIK3CDABL1EGFR | |
| SCHEMBL5482233 | 0.76 | HTR6 (0.41) | KMT2AMEN1NR1H2NR1H3PIK3CD | |
| SCHEMBL1053697 | 0.76 | ALDH1A1 (0.46) | NR1H2PIK3CDABL1EGFRHCK | |
| SCHEMBL691666 | 0.74 | NOTUM (0.59) | NR1H2NR1H3PIK3CDABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691814-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1707566-A1 | Deazapurines and uses thereof | Eisai Co., Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1474425-A1 | DEAZAPURINES AND USES THEREOF | Eisai Co. Ltd. (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | KMT2A 1590/4885MEN1 3643/4885NR1H2 3913/4885 |
| US-20050124649-A1 | Deazapurines and uses thereof | TPMT, CD38, CD2 | KMT2A 1654/4885MEN1 3746/4885NR1H2 3946/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | KMT2A 963/4885MEN1 3607/4885NR1H2 1772/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | KMT2A 2445/4885MEN1 3362/4885NR1H2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.